Luye Pharma finalises US$180 million 5.25% convertible bond issue maturing 2031

Bulletin Express06-11

Hong Kong-listed Luye Pharma Group Ltd. has completed the issuance of US$180.00 million 5.25% convertible bonds due 2031, following satisfaction of all conditions under the subscription agreement. Settlement and listing on the Vienna Stock Exchange occurred on 10 June 2026.

Key terms • Size and coupon: US$180.00 million, 5.25% per annum, due 2031 • Initial conversion price: HK$2.71 per share, implying a 24.9% premium to the HK$2.17 closing price on 3 June 2026 and a 24.1% premium to the five-day VWAP of HK$2.184 up to 2 June 2026 • Listing venue: Vienna Stock Exchange (Official Market) • Investor base: All initial placees are independent third parties and not connected persons of the company

Use of proceeds Net proceeds of approximately US$177.20 million are earmarked for refinancing existing indebtedness—including funding the concurrent repurchase of outstanding securities—and for general corporate purposes.

Subsequent steps The concurrent repurchase process is underway; the company will update the market upon completion.

Governance note The board comprises four executive directors, two non-executive directors, and five independent non-executive directors, chaired by Liu Dian Bo.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156409311?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156409311","market":"hk","top_or_hot":-1,"title":"Luye Pharma finalises US$180 million 5.25% convertible bond issue maturing 2031","media":"Bulletin Express","content":"<p>Hong Kong-listed Luye Pharma Group Ltd. has completed the issuance of US$180.00 million 5.25% convertible bonds due 2031, following satisfaction of all conditions under the subscription agreement. Settlement and listing on the Vienna Stock Exchange occurred on 10 June 2026.</p>\n<p>Key terms  \n• Size and coupon: US$180.00 million, 5.25% per annum, due 2031  \n• Initial conversion price: HK$2.71 per share, implying a 24.9% premium to the HK$2.17 closing price on 3 June 2026 and a 24.1% premium to the five-day VWAP of HK$2.184 up to 2 June 2026  \n• Listing venue: Vienna Stock Exchange (Official Market)  \n• Investor base: All initial placees are independent third parties and not connected persons of the company</p>\n<p>Use of proceeds  \nNet proceeds of approximately US$177.20 million are earmarked for refinancing existing indebtedness—including funding the concurrent repurchase of outstanding securities—and for general corporate purposes.</p>\n<p>Subsequent steps  \nThe concurrent repurchase process is underway; the company will update the market upon completion.</p>\n<p>Governance note  \nThe board comprises four executive directors, two non-executive directors, and five independent non-executive directors, chaired by Liu Dian Bo.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Luye Pharma finalises US$180 million 5.25% convertible bond issue maturing 2031</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLuye Pharma finalises US$180 million 5.25% convertible bond issue maturing 2031\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-11 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong-listed Luye Pharma Group Ltd. has completed the issuance of US$180.00 million 5.25% convertible bonds due 2031, following satisfaction of all conditions under the subscription agreement. Settlement and listing on the Vienna Stock Exchange occurred on 10 June 2026.</p>\n<p>Key terms  \n• Size and coupon: US$180.00 million, 5.25% per annum, due 2031  \n• Initial conversion price: HK$2.71 per share, implying a 24.9% premium to the HK$2.17 closing price on 3 June 2026 and a 24.1% premium to the five-day VWAP of HK$2.184 up to 2 June 2026  \n• Listing venue: Vienna Stock Exchange (Official Market)  \n• Investor base: All initial placees are independent third parties and not connected persons of the company</p>\n<p>Use of proceeds  \nNet proceeds of approximately US$177.20 million are earmarked for refinancing existing indebtedness—including funding the concurrent repurchase of outstanding securities—and for general corporate purposes.</p>\n<p>Subsequent steps  \nThe concurrent repurchase process is underway; the company will update the market upon completion.</p>\n<p>Governance note  \nThe board comprises four executive directors, two non-executive directors, and five independent non-executive directors, chaired by Liu Dian Bo.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02186","symbol_name":"绿叶制药","start_time":0,"source_url":"","article_id":"1156409311","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156409311","pubTimestamp":1781136180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong-listed Luye Pharma Group Ltd. has completed the issuance of US$180.00 million 5.25% convertible bonds due 2031, following satisfaction of all conditions under the subscription agreement....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02186":"绿叶制药"},"translate_title":"绿叶制药完成发行1.8亿美元5.25%2031年到期可转债","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":1},"content_text":"Hong Kong-listed Luye Pharma Group Ltd. has completed the issuance of US$180.00 million 5.25% convertible bonds due 2031, following satisfaction of all conditions under the subscription agreement. Settlement and listing on the Vienna Stock Exchange occurred on 10 June 2026.\nKey terms  \n• Size and coupon: US$180.00 million, 5.25% per annum, due 2031  \n• Initial conversion price: HK$2.71 per share, implying a 24.9% premium to the HK$2.17 closing price on 3 June 2026 and a 24.1% premium to the five-day VWAP of HK$2.184 up to 2 June 2026  \n• Listing venue: Vienna Stock Exchange (Official Market)  \n• Investor base: All initial placees are independent third parties and not connected persons of the company\nUse of proceeds  \nNet proceeds of approximately US$177.20 million are earmarked for refinancing existing indebtedness—including funding the concurrent repurchase of outstanding securities—and for general corporate purposes.\nSubsequent steps  \nThe concurrent repurchase process is underway; the company will update the market upon completion.\nGovernance note  \nThe board comprises four executive directors, two non-executive directors, and five independent non-executive directors, chaired by Liu Dian Bo.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156409311","isCrawlerRequest":true}